MedTrace Logo

Gene Expression in Hyperparathyroidism

NCT03044600 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2019-05-23

No results posted yet for this study

Summary

Objectives:

1. To better define the differences in molecular genetics of parathyroid tumors in patients with MEN1, single gland parathyroid disease in patients less than 50 years old and single gland disease in patients greater than 50 years old.
2. To better define the incidence of HRPT2 mutation in young patients with primary hyperparathyroidism and determine whether routine testing in these patients is indicated.

Conditions

  • Parathyroid Disease
  • Hyperparathyroidism

Interventions

OTHER

Chart Review

Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.

OTHER

HRPT2 Mutation Evaluation

Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Nancy D. Perrier, MD · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-07
Primary Completion
2017-10-18
Completion
2017-10-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03044600 on ClinicalTrials.gov